Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
Date:3/8/2012

the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication, regulatory review and potential approval of Arena's most advanced drug candidate, lorcaserin; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review is uncertain and Arena's applications for regulatory approval of lorcaserin may not be reviewed when anticipated; the EU application is subject to acceptance and confirmation by the EU regulatory agency that it is sufficiently complete to permit a substantive review; the FDA may not complete its review of the lorcaserin application by the PDUFA date; the occurrence, timing and results of FDA advisory committee meetings relating to lorcaserin and other drug candidates; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review or approval; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the tim
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
2. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
3. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
4. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
6. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
8. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
9. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
11. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 A lot of discussion in the ... treating  certain illnesses, injuries, or conditions. As medical science advances, ... methods with ones that they consider to be more cutting ... not one textbook method of treatment that stands out as ...
(Date:1/23/2015)...  The Partnership to Fight Chronic Disease (PFCD) released a public opinion ... a new study analyzing the impact of increased cost sharing on ... working to educate policy makers and the public on the costs ... on how the Iowa healthcare exchange could ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... filed suit today against Johnson & Johnson, Inc. and DePuy ... of the DePuy ASR XL Acetabular Hip Replacement System that ... of John David Hart in Fort Worth, Texas, is the ... United States District Court for the Eastern District of Texas ...
... (Becton, Dickinson and Company) (NYSE: BDX ), ... of its acquisition of Accuri Cytometers, Inc., an Ann ... cytometers for researchers. The acquisition expands BD,s ... and helps expand the use of flow cytometry technology ...
Cached Medicine Technology:DePuy Recalled Hip Device Lawsuit Filed in East Texas 2BD Completes Acquisition of Accuri Cytometers, Inc. 2
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... of vegetables and fruits could be worse than abusing alcohol ... ,It has been estimated that the minimum recommended daily ... vegetables at least. ,According to the 2005 ... accounted for a disability adjusted life years (DALY) rating of ...
... Researchers have confirmed that their studies on bacteria that ... widespread and persistent ear infections// that irritate kids, which ... is pointless. ,Otitis media, a condition of ... to visit doctor and or antibiotic prescriptions in the ...
... science and microbiology and molecular genetics, and his colleagues from ... the ability and potential for growing flu virus. , ... production of new human flu vaccines which is cheaper and ... He identified the new cell line while working on the ...
... are taking part in an initiative to gauge if ... people who have suffered a stroke recently//. The MíTICO ... Isquemic Ictus. ,The study included patients from different ... to three months previously. By means of periodical controls, ...
... is working on four vaccines, including those for treating ... currently working on four vaccines for anthrax, dengue, Japanese ... anthrax vaccine have been completed, which is ready for ... told reporters here today., ,The company would also ...
... wireless device that measures the acidity of stomach contents ... of the nose pain and throat discomfort// associated with ... reflux disease. ,However, while the new technology ... was better for diagnosing or managing these patients, said ...
Cached Medicine News:Health News:‘Biofilms’-Clumped Bacterial Slime Cause Ear Infecti 2Health News:New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine 2Health News:New Reflux Disease Technology More Comfortable, Not More Effective 2Health News:New Reflux Disease Technology More Comfortable, Not More Effective 3
The CdTOX A OIA gets the results you need without specimen extraction or instrumentation. Results are available in minutes vs hours or days for EIA or other methods. The combination of performance, ...
... for Botox therapy and nerve block ... injectable needle has a precisely machined ... with an attached 61-cm (24-in) lead ... insertion. Single patient use only. A ...
... Back Relief Apron has standard ... the weight from the shoulders ... aid of a 6" wide ... strap keeps apron snug. Belts ...
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
Medicine Products: